Biotech Values

[DewDiligence]

BMY thinks Milvexian can become a $4B drug by the end of the decade, according to today’s webcast and slide presentation (#msg-166786099). Milvexian has potential in both venous and arterial anticoagulation, which is something the FXa inhibitors, such as Eliquis, do not have.